AMNEAL PHARMACEUTICALS INC (AMRX) Stock Income Statement
NASDAQ:AMRX - US03168L1052 - Common Stock
9.55 USD
+0.19 (+2.03%)
9.64 USD
+0.09 (+0.94%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.85B | 2.79B | 2.39B | 2.21B | 2.09B | |||
| Minority Interest Expense | -47.87M | -43.01M | -35.27M | 124.80M | -9.55M | |||
| Cost Of Goods | 1.78B | 1.77B | 1.54B | 1.42B | 1.30B | |||
| Gross Profit | 1.07B | 1.02B | 856.66M | 795.82M | 791.66M | |||
| Operating Expenses | 694.75M | 672.07M | 581.82M | 596.52M | 575.27M | |||
| Research and Development | 203.37M | 190.71M | 163.95M | 195.69M | 201.85M | |||
| Selling, General, and Administrative Expenses | 497.54M | 482.28M | 433.50M | 404.06M | 373.22M | |||
| Operating Income | 379.82M | 348.37M | 274.85M | 199.30M | 216.40M | |||
| Interest Income/Expense | -242.10M | -265.44M | -208.96M | -170.74M | -136.68M | |||
| Other Income/Expense | -44.92M | -38.90M | -35.69M | 17.54M | 15.33M | |||
| Non Recurring Items | -3.50M | -99.05M | -70.47M | -294.23M | -63.68M | |||
| Income Before Taxes | 89.30M | -55.01M | -40.27M | -248.13M | 31.37M | |||
| Income Tax | 38.06M | 18.86M | 8.45M | 6.66M | 11.20M | |||
| Net Income | 3.38M | -116.89M | -83.99M | -129.99M | 10.62M | |||
| EBITDA | 625.19M | 584.56M | 504.25M | 439.48M | 449.80M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.01 | -0.38 | -0.48 | -0.86 | 0.07 | |||
| Non GAAP EPS | 0.74 | 0.58 | 0.64 | 0.68 | 0.84 | |||
| Statistics | ||||||||
| Gross Profit Margin | 37.67% | 36.52% | 35.79% | 35.97% | 37.81% | |||
| Profit Margin | 0.12% | -4.18% | -3.51% | -5.88% | 0.51% | |||
| Operating Profit Margin | 13.31% | 12.47% | 11.48% | 9.01% | 10.34% | |||
All data in USD